Solifenacin succinate for the treatment of symptoms of overactive bladder

Maniscalco, Maria; Singh-Franco, Devada; Wolowich, William R.; Torres-Colón, Rolando

doi:10.1016/j.clinthera.2006.09.017

Cited by 51 publications

(39 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Solifenacin has the longest elimination half-life of all antimuscarinics, and steady state serum concentration is achieved after 10 days of consecutive dosing. 48,49 Fesoterodine is a nonspecific, competitive muscarinic receptor antagonist that, by itself, is not a potent antimuscarinic agent. A matrix platform is used for the ER delivery of fesoterodine.…”

Section: Darifenacin Solifenacin and Fesoterodinementioning

confidence: 99%

Update on the management of overactive bladder: patient considerations and adherence

Dmochowski¹,

Gomelsky²

2010

RRU

View full text Add to dashboard Cite

Overactive bladder (OAB) is a common condition that causes a profound impact on an individual's overall health and quality of life. Muscarinic receptor antagonists are the mainstay of oral pharmacotherapy for OAB. Although all of the medications in this class are significantly more effective than placebo, they are also associated with more adverse events that may limit their overall use. Although newer preparations of these medications have sought to improve tolerability and efficacy through alternative routes of delivery and once-daily dosing, improved adherence to treatment and treatment persistence continue to be an ongoing challenge. An improved understanding of the factors involved in persistence of medical OAB therapy is imperative in efforts to optimize therapeutic benefits in this chronic and potentially morbid condition.

show abstract

Section: Darifenacin Solifenacin and Fesoterodinementioning

confidence: 99%

Update on the management of overactive bladder: patient considerations and adherence

Dmochowski¹,

Gomelsky²

2010

RRU

View full text Add to dashboard Cite

show abstract

“…It is highly selective for muscarinic M3 receptor which is believed to be important in the modulation of bladder function. It reduces smooth muscle tone in the bladder, allowing the bladder to retain larger volumes of urine and reducing the number of micturition, urgency and incontinence episodes [1,2].…”

Section: Introductionmentioning

confidence: 99%

Liquid Chromatographic Determination of Solifenacin Succinate, Flavoxate Hydrochloride and Tolterodine Tartrate in Bulk Drugs and Their Pharmaceutical Dosage Forms

Attia

Frag

Ahmed

2016

J. Chil. Chem. Soc.

View full text Add to dashboard Cite

A simple, precise, specific and accurate reversed phase HPLC (RP-HPLC) method has been developed for the determination of solifenacin succinate (SOLS), flavoxate HCl (FLXHC) and toltoridine tartarate (TOLT) in bulk and pharmaceutical dosage forms. The proposed RP-HPLC method was carried out using Xterra RP-18 column (5 μm practical size, 25 cm x 4.6 mm i.d.). The flow rate, the injection volume and the detection wavelength were 1.0 mL/min, 20 mL and 200 nm, respectively. The mobile phase consisted of 0.05 M pentane sulfonic acid sodium salt (SOLS: pH 3.0±0.05, FLXHC and TOLT: pH 5.5±0.05) and acetonitrile (50:50 v/v). The retention times for SOLS, FLXHC and TOLT drugs were found to be 4.1±0.1 min, 4.3±0.0 min and 5.8±0.1 min, respectively. The calibration was linear over the concentration range of 0.1-100 μg/mL. The mean recoveries for SOLS, FLXHC and TOLT drugs were about 99.80%, 100.43% and 100.00%, respectively. The method was validated according to the ICH guidelines with respect to specificity, linearity, accuracy, precision and robustness.

show abstract

“…Despite the presence of side effects and the high percentage of patients discontinuing treatment after a few months, they represent the first-line pharmacological therapy recommended for OAB treatment [8]. Solifenacin succinate is an effective muscarinic receptor antagonist with selectivity for M3 receptor in the urinary bladder [9]. It has shown significant improvement of the symptoms compared with placebo in patients with OAB [10,11].…”

Section: Introductionmentioning

confidence: 99%

Comparison of Therapeutic Efficacy and Urodynamic Findings of Solifenacin Succinate versus Mirabegron in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Study

Scaldazza¹,

Morosetti²

2016

Urol Int

View full text Add to dashboard Cite

Introduction: We assessed clinical and urodynamic effects of solifenacin versus mirabegron in women with overactive bladder (OAB) syndrome. Material and Methods: Eighty women with OAB were randomized into 2 groups. In group A, the patients received solifenacin 5 mg once a day for 12 weeks; in group B, the patients received mirabegron 50 mg once a day for 12 weeks. Symptoms were assessed with OAB Symptom Score (OABSS). Patients underwent urodynamic investigation with pressure flow study. OABSS and urodynamic study were performed before and after treatment. Results: Both solifenacin and mirabegron were effective in improving OAB symptoms. Mirabegron showed greater tolerability with fewer patients discontinuing therapy because of side effects. Both solifenacin and mirabegron were effective in improving the storage function in the pressure flow study, but solifenacin showed a significant reduction of the detrusor pressure in the voiding phase with an increase in the postvoid residual urine volume. Conclusions: Mirabegron has shown to be a drug with the better balance between efficacy and tolerability in women with OAB.

show abstract

Solifenacin succinate for the treatment of symptoms of overactive bladder

Cited by 51 publications

References 38 publications

Update on the management of overactive bladder: patient considerations and adherence

Update on the management of overactive bladder: patient considerations and adherence

Liquid Chromatographic Determination of Solifenacin Succinate, Flavoxate Hydrochloride and Tolterodine Tartrate in Bulk Drugs and Their Pharmaceutical Dosage Forms

Comparison of Therapeutic Efficacy and Urodynamic Findings of Solifenacin Succinate versus Mirabegron in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Study

Contact Info

Product

Resources

About